DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8497240B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 17, 2007 |
| Grant date | Jul 30, 2013 |
| Priority date | — |
| Expiry date | Mar 13, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.